N-[11C]Methyl-AMD3465 PET as a Tool for In Vivo Measurement of Chemokine Receptor 4 (CXCR4) Occupancy by Therapeutic Drugs

doi:10.1007/s11307-016-1028-8

Paper

N-[11C]Methyl-AMD3465 PET as a Tool for In Vivo Measurement of Chemokine Receptor 4 (CXCR4) Occupancy by Therapeutic Drugs

Published Nov 28, 2016 · S. Hartimath, M. Khayum, A. van Waarde

Molecular Imaging and Biology

Q2 SJR score

13

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

PurposeChemokine receptor 4 (CXCR4) is overexpressed in many cancers and a potential drug target. We have recently developed the tracer N-[11C]methyl-AMD3465 for imaging of CXCR4 expression by positron emission tomography (PET). We investigated the pharmacokinetics of N-[11C]methyl-AMD3465 in rats bearing a C6 tumor and assessed whether the CXCR4 occupancy by the drug Plerixafor® can be measured with this PET tracer.ProcedureA subcutaneous C6 tumor was grown in Wistar rats. Dynamic N-[11C]methyl-AMD3465 PET scans with arterial blood sampling was performed in control rats and rats pretreated with Plerixafor® (30 mg/kg, s.c). The distribution volume (VT) of the tracer was estimated by compartment modeling with a two-tissue reversible compartment model (2TRCM) and by Logan graphical analysis. The non-displaceable binding potential (BPND) was estimated with the 2TRCM. Next, CXCR4 receptor occupancy of different doses of the drug Plerixafor® (0.5–60 mg/kg) was investigated.ResultsThe tumor could be clearly visualized by PET in control animals. Pretreatment with 30 mg/kg Plerixafor® significantly reduced tumor uptake (SUV 0.65 ± 0.08 vs. 0.20 ± 0.01, p < 0.05). N-[11C]Methyl-AMD3465 was slowly metabolized in vivo, with 70 ± 7% of the tracer in plasma still being intact after 60 min. The tracer showed reversible in vivo binding to its receptor. Both 2TRCM modeling and Logan graphical analysis could be used to estimate VT. Pre-treatment with 30 mg/kg Plerixafor® resulted in a significant reduction in VT (2TCRM 0.87 ± 0.10 vs. 0.23 ± 0.12, p < 0.05) and BPND (1.85 ± 0.14 vs. 0.87 ± 0.12, p < 0.01). Receptor occupancy by Plerixafor® was dose-dependent with an in vivo ED50 of 12.7 ± 4.0 mg/kg. Logan analysis gave comparable results.ConclusionN-[11C]Methyl-AMD3465 PET can be used to visualize CXCR4 expression and to calculate receptor occupancy. VT determined by Logan graphical analysis is a suitable parameter to assess CXCR4 receptor occupancy. This approach can easily be translated to humans and used for early drug development and optimization of drug dosing schedules.

Non-RCT

Animal Study

Rigorous Journal

Study Snapshot

N-[11C]methyl-AMD3465 PET can visualize CXCR4 expression and measure receptor occupancy, aiding in early drug development and optimizing drug dosing schedules.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

N-[11C]Methyl-AMD3465 PET as a Tool for In Vivo Measurement of Chemokine Receptor 4 (CXCR4) Occupancy by Therapeutic Drugs

Sign up to use Study Snapshot

References

Evaluation of N-[(11)C]methyl-AMD3465 as a PET tracer for imaging of CXCR4 receptor expression in a C6 glioma tumor model.

N-[(11)C]methyl-AMD3465 is a promising PET tracer for noninvasively detecting CXCR4 expression in tumors and other CXCR4 expressing tissues, warranting further evaluation for potential clinical applications.

Molecular Imaging of Death Receptor 5 Occupancy and Saturation Kinetics In Vivo by Humanized Monoclonal Antibody CS-1008

111In-labeled anti-DR5 antibody CS-1008 can effectively determine receptor occupancy and effective dose levels of DR5 agonist antibodies in cancer patients.

[⁹⁹mTc]O₂-AMD3100 as a SPECT tracer for CXCR4 receptor imaging.

[99mTc]O2-AMD3100 shows potential as a non-invasive imaging tracer for CXCR4 receptors, showing specific binding in organs with high CXCR4 expression and CXCR4 positive tumors.

CXCL12 mediates apoptosis resistance in rat C6 glioma cells.

CXCL12 promotes glioma progression by mediating apoptosis resistance in rat C6 glioma cells, making it a useful model for studying these mechanisms in vitro and in vivo.

The chemokine network, a newly discovered target in high grade gliomas.

The chemokine network contributes to the progression of high grade gliomas by intensifying their invasive character, offering potential for targeted cancer drugs.

Chemokine receptor CXCR4 expression in hepatocellular carcinoma patients increases the risk of bone metastases and poor survival

CXCR4 expression in primary hepatocellular carcinomas may be an independent risk factor for bone metastasis and poor clinical outcome.

AMD3100 Is a CXCR7 Ligand with Allosteric Agonist Properties

AMD3100 is an allosteric agonist of CXCR7, with opposite effects on CXCR4 and CXCR7, requiring caution in using it as a tool to dissect CXCL12 effects on these receptors.

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.

The CXCR4 inhibitor AMD3100 disrupts multiple myeloma cells' interaction with the bone marrow microenvironment, enhancing their sensitivity to therapeutic agents and potentially improving cancer therapy efficacy.

64Cu-AMD3100--a novel imaging agent for targeting chemokine receptor CXCR4.

64 Cu-AMD3100 shows promise as a potential PET imaging agent for visualizing CXCR4-positive tumors and metastases, potentially guiding and monitoring anti-CXCR4 tumor therapy.

Citations

18F-Radiolabeling and Evaluation of an AMD3465 Derivative for PET Imaging of CXCR4 in a Mouse Breast Tumor Model.

[18F]SFB-AMD3465 shows promising potential as a targeted PET tracer for CXCR4, with CXCR4-dependent, specific, and sensitive uptake in a mouse breast tumor model.

Molecular Immune Targeted Imaging of Tumor Microenvironment

Novel PET imaging probes are being developed to track the dynamics of molecular targets in the tumor microenvironment, aiding in the development of targeted cancer therapies.

Investigating CXCR4 expression of tumor cells and the vascular compartment: A multimodal approach

The T140-MB, a targeted microbubble, effectively visualizes CXCR4 expression in the tumor vasculature, offering a cost-effective and radiation-free alternative to PET imaging for cancer therapy stratification and monitoring.

PET Imaging Radiotracers of Chemokine Receptors

Recent advances in PET radiotracer development for imaging various chemokine receptors, particularly CXCR4, CCR2, and CCR5, provide valuable insights into chemokine-related cancer and cardiovascular research.

Outcome prediction and evaluation by imaging the key elements of therapeutic responses to cancer immunotherapies using PET.

PET imaging of key elements of cancer immunotherapies can improve prediction, monitoring, and management, but requires more preclinical study and clinical validation.